ASA Monitor April 2024, Vol. 88, 14.
New statement on cerebral venous thrombosis
The American Heart Association released a statement to raise awareness about cerebral venous thrombosis (CVT) among patients and physicians for timely recognition and treatment. The statement reviews the latest evidence and updates recommendations for diagnosing and managing CVT, focusing on advancements in treatment approaches. CVT, a rare stroke type, accounts for less than 3% of all strokes, primarily impacting younger individuals, pregnant or postpartum women, oral contraceptive users, and those prone to blood clots. New risk factors identified include obesity and active COVID-19 infection. Diagnosing CVT is challenging due to symptoms that mimic other conditions. The statement suggests using new MRI techniques for venous system imaging to enhance diagnosis. Although 80%-90% achieve functional independence after CVT, residual symptoms are common. Anticoagulation therapy remains standard, with direct oral anticoagulants emerging as alternatives. Endovascular treatments, removing clots with catheters, and decompressive craniectomy may be considered for severe cases.
Source: asamonitor.pub/4biYVMx